How common are polivy's side effects experienced?

Polivy (polatuzumab vedotin) is associated with several common side effects. In trials, most patients experienced at least one adverse event, and some events were more likely to be serious. The exact frequency depends on the regimen (e.g., pola-R-CHP vs pola-BR) and the patient population.

Most commonly reported (all grades):
- Low blood cell counts (neutropenia, anemia, thrombocytopenia)
- Fatigue
- Infections (including fever)
- Nausea
- Diarrhea
- Decreased appetite
- Peripheral neuropathy (numbness, tingling, or pain in hands/feet)

More notable serious adverse events (grade 3–4) tend to include:
- Neutropenia with infection or fever
- Febrile neutropenia
- Anemia
- Thrombocytopenia
- Infections

Peripheral neuropathy can lead to dose modifications or delays in some patients. Other side effects (like mouth sores, skin reactions, or liver enzyme elevations) can occur but are less common.

If you’re asking about a specific Polivy-containing regimen (for example pola-R-CHP or pola-BR), I can give you the approximate frequencies from those trials or look up the latest labeling numbers. Also, if you have a particular side effect you’re worried about, tell me and I can explain that risk and how doctors typically manage it.

Note: I’m not a doctor. For personalized information about risks based on your health and treatment plan, please check the FDA labeling and talk with your oncologist or healthcare provider.